SPOTLIGHT: Tysabri ruling expected in March

Biogen Idec and Ireland's Elan say that they expect the FDA to decide in March whether or not it will allow the return of their MS drug Tysabri. Tysabri was pulled from the market in early 2005 after it was linked to a rare brain disorder. Report